Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Kyowa Kirin Co., Ltd., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 1949, the company has achieved significant milestones, including advancements in biopharmaceuticals and innovative drug development.
Kyowa Kirin focuses on core therapeutic areas such as oncology, nephrology, and immunology, offering unique products that leverage cutting-edge biotechnology. Their commitment to research and development has positioned them as a leader in the market, with notable achievements in creating treatments that address unmet medical needs. With a strong emphasis on quality and innovation, Kyowa Kirin continues to enhance patient outcomes globally.
+40 vs industry average
Kyowa Kirin’s score of 80 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Kyowa Kirin, a pharmaceutical preparation manufacturing company headquartered in Japan, has reported its carbon emissions across various scopes, demonstrating a commitment to climate action.
Recent Emissions Data:
Climate Commitments and Targets:
Kyowa Kirin is actively working towards emissions reduction. The company has set ambitious near-term targets:
In addition to these near-term goals, Kyowa Kirin is aligned with the Kirin Group's long-term vision of achieving net-zero greenhouse gas emissions across the entire value chain by 2050. This long-term ambition includes achieving carbon neutrality by 2050, with a focus on incorporating next-generation energy sources.
Science Based Targets initiative (SBTi):
Kyowa Co., Ltd., identified as a small and medium-sized enterprise (SME) in this context, has committed to reducing Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030 from a 2021 base year. This commitment also includes measuring and reducing its Scope 3 emissions. These targets are consistent with the reductions required to keep warming to 1.5°C.
Emissions Data Context:
For years prior to 2022, comprehensive Scope 3 emissions data was not fully disclosed. For instance, in 2021, 2020, 2019, 2018, and 2009, while Scope 1 and Scope 2 emissions (or total emissions in some cases) were reported, specific Scope 3 categories like "purchased goods and services" were either not disclosed or data was missing. For earlier years, like 2009, total emissions were reported as approximately 643,000,000 kg CO2e, with Scope 1, Scope 2, and Scope 3 data not specified.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 2
2030
42% reduction in Scope 1
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


Common questions about Kyowa Kirin’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more